Relenza Originator Aussie Biotech Biota Reports $37 Million In Royalties From GSK
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Melbourne-based Relenza developer Biota reported record-breaking royalties of $37.7 million from GlaxoSmithKline for FY2009, almost double the amount it reported a year ago